1. Home
  2. NRIX vs NTCT Comparison

NRIX vs NTCT Comparison

Compare NRIX & NTCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Nurix Therapeutics Inc.

NRIX

Nurix Therapeutics Inc.

HOLD

Current Price

$18.51

Market Cap

1.7B

Sector

Health Care

ML Signal

HOLD

Logo NetScout Systems Inc.

NTCT

NetScout Systems Inc.

HOLD

Current Price

$27.71

Market Cap

2.0B

Sector

Technology

ML Signal

HOLD

Company Overview

Basic Information
Metric
NRIX
NTCT
Founded
2009
1984
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
EDP Services
Sector
Health Care
Technology
Exchange
Nasdaq
Nasdaq
Market Cap
1.7B
2.0B
IPO Year
2020
1999

Fundamental Metrics

Financial Performance
Metric
NRIX
NTCT
Price
$18.51
$27.71
Analyst Decision
Strong Buy
Buy
Analyst Count
13
2
Target Price
$27.46
$31.00
AVG Volume (30 Days)
1.8M
534.6K
Earning Date
01-27-2026
01-29-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
1.24
Revenue
$83,687,000.00
$862,770,000.00
Revenue This Year
$59.40
$5.90
Revenue Next Year
N/A
$2.62
P/E Ratio
N/A
$22.34
Revenue Growth
48.32
9.60
52 Week Low
$8.18
$18.12
52 Week High
$22.50
$30.67

Technical Indicators

Market Signals
Indicator
NRIX
NTCT
Relative Strength Index (RSI) 55.34 54.36
Support Level $16.98 $26.74
Resistance Level $19.54 $28.12
Average True Range (ATR) 0.91 0.55
MACD -0.34 -0.04
Stochastic Oscillator 57.04 59.66

Price Performance

Historical Comparison
NRIX
NTCT

About NRIX Nurix Therapeutics Inc.

Nurix Therapeutics Inc is a biopharmaceutical company focused on the discovery, development and commercialization of oral, small molecule therapies designed to modulate cellular protein levels as a novel treatment approach for cancer and immune disorders. The company's pipeline comprises targeted protein degraders of Brutons tyrosine kinase, or BTK, a B-cell signaling protein, and inhibitors of Casitas B-lineage lymphoma proto-oncogene-B, or CBL-B, an E3 ligase that regulates T cell activation. Its drug candidate from protein degradation portfolio, NX-2127, is an orally available BTK degrader for the treatment of relapsed or refractory B-cell malignancies.

About NTCT NetScout Systems Inc.

NetScout Systems Inc is a provider of service assurance and cybersecurity solutions to enterprise and government networks. It bases its solutions on proprietary adaptive service intelligence technology, which helps customers monitor and identify performance issues and provides insight into network-based security threats. These solutions also deliver real-time and historical information, which provides insight to restore service and understand the quality of user experience. The company derives revenue from the sale of network management tools and security solutions. Its geographical regions include USA, which derives maximum revenue, Europe, Asia, and Rest of the World.

Share on Social Networks: